Design Therapeutics, Inc.

NasdaqGS:DSGN Rapporto sulle azioni

Cap. di mercato: US$296.7m

Design Therapeutics Crescita futura

Future criteri di controllo 0/6

Si prevede che gli utili di Design Therapeutics diminuiranno del 15.3% all'anno, mentre si prevede che il fatturato annuo crescerà del 86.5% all'anno. Si prevede che l'EPS diminuirà del 8.5% all'anno.

Informazioni chiave

-15.3%

Tasso di crescita degli utili

-8.5%

Tasso di crescita dell'EPS

Biotechs crescita degli utili26.9%
Tasso di crescita dei ricavi86.5%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento05 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Oct 04
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Jun 19
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Mar 15
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Nov 16
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Jun 06
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Feb 09
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Oct 25
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics GAAP EPS of -$0.27 misses by $0.02

Aug 08

We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Jul 02
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Mar 18
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Dec 03
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Aug 18
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics expands board of directors

Jun 07

Design Therapeutics EPS misses by $0.24

May 10

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:DSGN - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026N/A-75N/AN/A3
12/31/2025N/A-67N/AN/A3
12/31/2024N/A-54N/AN/A3
6/30/2024N/A-51-51-51N/A
3/31/2024N/A-59-54-54N/A
12/31/2023N/A-67-59-59N/A
9/30/2023N/A-72-61-61N/A
6/30/2023N/A-74-61-60N/A
3/31/2023N/A-69-58-57N/A
12/31/2022N/A-63-52-51N/A
9/30/2022N/A-57-46-45N/A
6/30/2022N/A-51-41-40N/A
3/31/2022N/A-43-39-38N/A
12/31/2021N/A-36-31-29N/A
9/30/20210-28-24-23N/A
6/30/20210-19-17-17N/A
3/31/20210-13-10-10N/A
12/31/20200-8-9-9N/A
12/31/20191-200N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che DSGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che DSGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che DSGN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che DSGN non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che DSGN non avrà alcun fatturato il prossimo anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di DSGN è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita